Second infield re‐irradiation with a resulting cumulative equivalent dose (EQD2max) of >180 Gy for patients with recurrent head and neck cancer
- 6 December 2018
- journal article
- research article
- Published by Wiley in Head & Neck
- Vol. 41 (4), E48-E54
- https://doi.org/10.1002/hed.25428
Abstract
Background For locally recurrent head and neck cancer, re‐irradiation with modern techniques like stereotactic body radiotherapy is a promising, possibly curative alternative to palliative systemic therapy. Methods We report on 1 patient with nasopharyngeal carcinoma (NPC) and 1 patient with cutaneous squamous cell carcinoma (SCC). Both patients received full dose primary treatment (>66 Gy, EQD2), full dose re‐irradiation (>50 Gy, EQD2), and a second course of re‐irradiation via robotic radiosurgery (CyberKnife) for a second local recurrence. Results Both treatments resulted in adequate tumor response. No grade III‐IV acute or late toxicities occurred. Follow‐up at 6 months after third irradiation showed partial remission for the patient with NPC. In the second case (SCC), no toxicities occurred and the tumor was in remission 18 months after last treatment. Conclusion These cases show that a second course of re‐irradiation utilizing modern techniques like robotic radiosurgery might be feasible for carefully selected patients with head and neck cancer.Keywords
This publication has 38 references indexed in Scilit:
- Salvage Reirradiaton With Stereotactic Body Radiotherapy for Locally Recurrent Head-and-Neck TumorsInternational Journal of Radiation Oncology*Biology*Physics, 2011
- Stereotactic Body Radiation Therapy for Head and Neck Tumor: Disease Control and Morbidity OutcomesJournal of Radiation Research, 2011
- Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patientsRadiotherapy and Oncology, 2009
- Prognostic Factors for Survival After Salvage Reirradiation of Head and Neck CancerJournal of Clinical Oncology, 2009
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerThe New England Journal of Medicine, 2008
- Phase II Study of Low-Dose Paclitaxel and Cisplatin in Combination With Split-Course Concomitant Twice-Daily Reirradiation in Recurrent Squamous Cell Carcinoma of the Head and Neck: Results of Radiation Therapy Oncology Group Protocol 9911Journal of Clinical Oncology, 2007
- Reirradiation in squamous cell head and neck cancer: recent developments and future directionsCurrent Opinion in Oncology, 2007
- Phase III Randomized Trial of Cisplatin Plus Placebo Compared With Cisplatin Plus Cetuximab in Metastatic/Recurrent Head and Neck Cancer: An Eastern Cooperative Oncology Group StudyJournal of Clinical Oncology, 2005
- Hyperfractionated Accelerated Chemoradiation With Concurrent Fluorouracil-Mitomycin Is More Effective Than Dose-Escalated Hyperfractionated Accelerated Radiation Therapy Alone in Locally Advanced Head and Neck Cancer: Final Results of the Radiotherapy Cooperative Clinical Trials Group of the German Cancer Society 95-06 Prospective Randomized TrialJournal of Clinical Oncology, 2005
- Salvage surgery after radical accelerated radiotherapy with concomitant boost technique for head and neck carcinomasHead & Neck, 2004